USPTO grants patent

Stem Cell Sciences plc
25 July 2005

                                                                    25 July 2005



                              Stem Cell Sciences plc

        US Patent and Trademark Office grants Stem Cell Selection Patent

Stem Cell Sciences Ltd, (SCS) which recently listed on the London Stock
Exchange's Alternative Investment Market (AIM), announced today that the US
Patent and Trademark Office ("USPTO") has granted important additional claims to
the patented technology known as 'Stem Cell Selection'.

'Stem Cell Selection' refers to the methods and tools used to obtain pure
populations of stem cells used in drug discovery and cell therapies.

The new claims (US Patent 6,878,542) cover methods of enriching for any type of
mammalian stem cell, from any cell source, based on introduced genes such as
fluorescent markers or cell surface proteins. This extension broadens the
granted US claims to a similar scope to that already granted in other
territories including the EU.

SCS expects the broadening of the patent claims to generate considerable new
business through licensing of its technology to the US biopharmaceutical
industry.

Dr Tim Allsopp, Chief Scientific Officer of Stem Cell Sciences explained "Having
a sophisticated technology to derive highly purified populations of stem cells,
for example, nerve, heart, liver or blood stem cells, is a fundamental
requirement for almost all stem cell applications, including cell therapies".

Dr Peter Mountford, President and CEO of Stem Cell Sciences, said, "This is a
very important technology for our field.  SCS is committed to facilitating broad
access to its key technologies and reagents in order to advance stem cell
research and development. The valuable 'tool box' nature of this technology has
already provided multi-million dollar revenues for the Company. Developing new
research partnerships and licensing agreements in the USA for the 'Stem Cell
Selection' technology is an important component of the Company's plans to
establish US based operations in 2006."

The creation of Stem Cell Sciences USA will be the fourth leg of the Stem Cell
Sciences global alliance, which includes science and business teams at Stem Cell
Sciences UK (Edinburgh, UK), Stem Cell Sciences KK  (Kobe, Japan) and Stem Cell
Sciences Ltd (Melbourne, Australia)".

Further information at www.stemcellsciences.com or contact:

            Nicky Hawkins, Trimedia Communications
            Telephone: [phone]
            Email: [e-mail]


Notes to Editors:

Stem cells are undifferentiated (un-specialised) cells which can divide to make
copies of themselves or differentiate (change) to become specialised cells of a
specific tissue such as neural cells or bloom cells.

Stem Cell Sciences plc:  Stem Cell Sciences Australia was founded in 1994 to
commercialise the stem cell research of Professor Austin Smith and Dr Peter
Mountford at the University of Edinburgh.  In 2000 Stem Cell Sciences UK was
established, followed by Stem Cell Sciences KK Japan in April 2002, with the
objective of collaborative research with the RIKEN Centre for Developmental
Biology (RIKEN CDB) in Kobe, Japan.  In July 2003, with the incorporation of
Stem Cell Sciences Holdings in Scotland, Edinburgh became the Group's
headquarters. On July 18 2005 Stem Cell Sciences plc listed on the London Stock
Exchange's Alternative Investment Market (AIM).



                      This information is provided by RNS
            The company news service from the London Stock Exchange      MSCDGGZNRZZGKZM